Kyverna Therapeutics, Inc. KYTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$39.73M+11.0% | -$37.8M-0.8% | -$36.79M-6.7% | -$42.08M-46.1% | -$44.64M-67.2% | ||
| $351K-29.9% | $368K-34.6% | $415K-25.6% | $515K-2.8% | $501K+3.9% | ||
| $3.17M+46.7% | $2.7M+95.5% | $2.7M-20.9% | $2.52M+96.1% | $2.16M-5.1% | ||
| $6.28M+65.8% | $2.15M— | -$6.8M-234% | $1.41M— | $3.78M+23.3% | ||
| -$6.88M-281% | $3.03M+584% | $1.99M+15.8% | $1.89M+39.2% | -$1.8M-24.5% | ||
| $5K-99.0% | —— | $958K+44.5% | —— | $515K+75.8% | ||
| -$503K+47.8% | -$844K-30.4% | -$774K-24.6% | -$758K-24.1% | -$963K-85.2% | ||
| -$41.6M+7.4% | -$33.53M+9.5% | -$43.32M-57.6% | -$31.95M-32.2% | -$44.92M-76.0% | ||
| —— | —— | $2K-98.0% | $4K-99.6% | $0-100% | ||
| -$50.2M-1,000% | —— | $22.56M— | $29.17M+143% | $5.58M+105% | ||
| —— | $6.18M— | $6.18M— | $6.18M— | $6.18M— | ||
| $243K+8,000% | $15.29M+6,834% | $1.65M+1,734% | $0-100% | $3K-95.3% | ||
| $86K-74.8% | $85K-65.6% | $120K-50.2% | $262K+6.9% | $341K+47.6% | ||
| —— | —— | —— | —— | —— | ||
| -$101K+75.6% | $140.74M— | $1.49M— | -$649K— | -$414K-100% | ||
| -$91.9M-131% | $89.93M— | -$19.28M— | -$3.43M— | -$39.75M-121% | ||
| $568K+2,889% | $370K+1,270% | $8K-75.8% | $18K-52.6% | $19K-56.8% | ||
| $730K-65.4% | $1.37M-38.8% | $1.57M-45.8% | $1.84M-18.3% | $2.11M+654% | ||
| $0-100% | —— | —— | —— | $648K— | ||
| —— | -$625K— | -$625K— | -$625K— | -$625K— | ||
| -$6.88M-281% | $3.03M+584% | $1.99M+15.8% | $1.89M+39.2% | -$1.8M-24.5% | ||
| -$503K+47.8% | -$844K-30.4% | -$774K-24.6% | -$758K-24.1% | -$963K-85.2% | ||
| -$4.35M-88.7% | -$644K-108% | -$1.17M-278% | $3.32M+23.4% | -$2.31M-3,148% | ||
| -$66K-117% | -$58K-107% | —— | -$2.35M+24.3% | $380K-85.2% | ||
| $114K— | —— | —— | —— | $0— | ||
| $619K-12.1% | $749K+9.3% | $732K+8.9% | $715K+8.2% | $704K+33.8% | ||
| $86K-74.8% | $85K-65.6% | $120K-50.2% | $262K+6.9% | $341K+47.6% | ||
| $189K— | $50K— | $43K— | $51K— | $0— | ||
| $69K-9.2% | $63K— | $0— | $336K-17.2% | $76K-97.4% | ||
| —— | $98.97M— | $0— | $0— | $0-100% | ||
| -$503K+47.8% | -$844K-30.4% | -$774K-24.6% | -$758K-24.1% | -$963K-85.2% | ||
| $5.24M— | $194K— | $0— | $0— | $0-100% | ||
| $123K-43.3% | —— | —— | —— | $217K-46.6% | ||
| —— | -$33.53M+10.8% | -$43.32M-57.0% | -$31.95M-26.8% | -$44.92M-72.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kyverna Therapeutics, Inc. generate?
- Kyverna Therapeutics, Inc. (KYTX) generated -$150.4M in operating cash flow over the trailing twelve months.
- What is Kyverna Therapeutics, Inc.'s free cash flow?
- After $538.0K of capital expenditures, Kyverna Therapeutics, Inc.'s free cash flow was -$153.7M over the trailing twelve months, down 32.0% year over year.
- Where does Kyverna Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Kyverna Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.